Table 3.

Factors associated with recurrence of hepatocellular carcinoma after completing antiviral therapy in patients who achieved SVR

Factor	Univariate analysis		Multivariate analysis
	Odds ratio (95% CI)	p	Odds ratio (95% CI)	p
Age	0.991 (0.957–1.027)	0.6024
Sex (male)	0.628 (0.319–1.186)	0.1537
Past history of IFN (yes)	0.786 (0.421–1.477)	0.4495
Resolved HBV infection (yes)	1.432 (0.767–2.691)	0.2581
Number of HCC treatments before DAA (≥3 times)	2.709 (1.366–5.235)	0.0051	1.7163 (0.8045–3.5598)	0.1589
Number of days from HCC treatment to DAA	0.998 (0.997–0.999)	0.0009	0.9998 (0.9975–0.9997)	0.0064
HCC stage III at initial treatment	1.799 (0.824–3.629)	0.1336
HCC stage III at treatment just before DAA	2.193 (0.694–5.954)	0.1671
Number of tumors (≥3) at treatment just before DAA	3.374 (1.699–6.544)	0.0008	2.0633 (0.9623–4.3238)	0.0624
Maximum tumor diameter (≥2.5 cm) at treatment just before DAA	1.231 (0.489–4.129)	0.6874
Platelet count (at start of DAA)	0.959 (0.890–1.029)	0.2537
Albumin (at the beginning DAA)	0.973 (0.479–1.954)	0.9400
Prothrombin time (at start of DAA)	0.996 (0.978–1.016)	0.7018
Fibrosis-4 index (at start of DAA)	0.996 (0.913–1.059)	0.9050
AFP (at end of DAA treatment) <8 vs ≥8 (≥8)	1.031 (1.009–1.047)	0.0091	2.6695 (1.2462–5.5706)	0.0123
	2.507 (1.285–4.782)	0.0078
DCP (at end of DAA treatment)	1.004 (0.999–1.008)	0.0681
ALT (at end of DAA treatment)	0.999 (0.964–1.031)	0.9674
Anti-HBs change ratio	0.058 (0.001–2.090)	0.1384
Anti-HBc change ratio	0.163 (0.014–3.476)	0.2212

AFP, α-fetoprotein; ALT, alanine aminotransferase; DAA, direct-acting antiviral; DCP, des-gamma-carboxy prothrombin; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; IFN, interferon; SVR, sustained virologic response

Anti-HBs change ratio = anti-HBs level at the end of DAA therapy/anti-HBs level before DAA

Anti-HBc change ratio = anti-HBc level at the end of DAA therapy/anti-HBc level before DAA